利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.051 秒)

    Inhibitor compounds of phosphodiesterase type 10A
    14.
    发明授权
    Inhibitor compounds of phosphodiesterase type 10A 有权
    磷酸二酯酶10A型抑制剂化合物

    公开(公告)号：US09163019B2

    公开(公告)日：2015-10-20

    申请号：US14208067

    申请日：2014-03-13

    申请人： AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

    发明人： Hervë Geneste ,  Michael Ochse ,  Karla Drescher ,  Berthold Behl ,  Loic Laplanche ,  Jürgen Dinges ,  Clarissa Jakob

    IPC分类号： A61K31/54 ,  C07D471/02 ,  C07D471/04 ,  C07D519/00

    CPC分类号： C07D471/04 ,  C07D519/00

    摘要： The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims.The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

    摘要翻译： 本发明涉及式I化合物，N-氧化物，互变异构体，前药及其药学上可接受的盐：在式I中，变量Het，A，X，Y，Z，R1，R2，R3，R4， R5和Q如权利要求中所定义。 式I化合物，N-氧化物，互变异构体，其前药和药学上可接受的盐是10A型磷酸二酯酶的抑制剂。 因此，本发明还涉及式I化合物，N-氧化物，互变异构体，前药和其药学上可接受的盐在制备药物中的用途，因此其适用于治疗或控制医学病症 选自神经障碍和精神障碍，用于改善与这种障碍相关的症状并降低这种障碍的风险。

    Inhibitor compounds of phosphodiesterase type 10A
    16.
    发明授权
    Inhibitor compounds of phosphodiesterase type 10A 有权
    磷酸二酯酶10A型抑制剂化合物

    公开(公告)号：US09475808B2

    公开(公告)日：2016-10-25

    申请号：US14854835

    申请日：2015-09-15

    申请人： AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

    发明人： Hervé Geneste ,  Michael Ochse ,  Karla Drescher ,  Berthold Behl ,  Loic Laplanche ,  Jürgen Dinges ,  Clarissa Jakob

    IPC分类号： A61K31/54 ,  C07D471/04 ,  C07D519/00

    CPC分类号： C07D471/04 ,  C07D519/00

    摘要： The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims.The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

    摘要翻译： 式I化合物，N-氧化物，互变异构体，其前药和药学上可接受的盐是10A型磷酸二酯酶的抑制剂。 因此，本发明还涉及式I化合物，N-氧化物，互变异构体，前药和其药学上可接受的盐在制备药物中的用途，因此其适用于治疗或控制医学病症 选自神经障碍和精神障碍，用于改善与这种障碍相关的症状并降低这种障碍的风险。